Updated: July 20, 2020 9:01:05 pm
Oxford Coronavirus (Covid-19) Vaccine: In a significant development, the Covid-19 vaccine jointly developed by British-Swedish company AstraZeneca and the University of Oxford has been found to be safe and induced an immune response in early-stage clinical trials. The AZD1222 vaccine, based on a chimpanzee adenovirus called ChAdOx1, elicited antibody and T-cell immune responses, according to results published in The Lancet medical journal on Monday.
The Oxford shot is one of the front runners in the vaccine race and is already undergoing a combined Phase II/III trials in the UK, Brazil and South Africa. AstraZeneca has signed deals to produce 400 million doses for the US and 100 million for the UK if it is successful in human trials.
According to the World Health Organization’s latest count, over two dozen experimental vaccines are being tested in humans and more than 160 are in earlier stages of development.
What is Oxford’s ChAdOx1 Covid-19 vaccine?
Oxford’s AZD1222 vaccine is made from a genetically engineered virus that causes the common cold in chimpanzees. However, the virus has been modified so that it doesn’t cause infection in people and also to mimic the coronavirus.
Scientists did this by transferring the genetic instructions of the coronavirus’ “spike protein” – the crucial tool it uses to invade human cells – to the vaccine. This was done so that the vaccine resembles the coronavirus and the immune system can learn how to attack it.
Earlier, the Oxford vaccine was tested on monkeys in a small study and had shown some promising results on them. Researchers involved with the ChAdOx1 vaccine trials said the candidate had shown signs of priming the rhesus macaque monkeys’ immune systems to fend off the deadly virus and showed no indications of adverse effects.
Moreover, research by Britain’s Pirbright Institute revealed that a study in pigs has found that two doses of the Oxford vaccine produced a greater antibody response than a single dose.
For phase I in April, 1,102 participants were recruited in multiple study sites in the UK. On May 22, Oxford announced that 1,000 immunisations “have been completed and follow-up is currently ongoing”.
Last month, Professor Adrian Hill, the director of the Jenner Institute at the University of Oxford, told a webinar of the Spanish Society of Rheumatology that the “best scenario” would see results from “clinical trials in August and September and deliveries from October”.
📣 The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines